On Monday, when the FDA came out against Sarepta Therapeutics’ (SRPT) Duchenne muscular dystrophy drug Vyondys 53, investors knew the shockwaves would immediately …
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, …
Wall Street loves growth stocks — and for good reason. In 2018, according to Bank of America, “growth” oriented mutual funds outperformed “value” …
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Deciphera Pharmaceuticals …
Foamix Pharmaceuticals (FOMX) may be the best drug stock opportunity you’ve never heard of — and you should probably prepare yourself to hear …
One week ago, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin (AMRN). He did this partly because he liked …
Foamix (FOMX) hasn’t had a great year, with shares falling 33% since the start of 2019. But things aren’t as bad as they …
In an acronym-heavy update, Stifel analyst Derek Archila reiterated his “buy” rating on anti-cholesterol drugmaker Amarin Corporation (AMRN) following the company’s Q2 earnings …
Generic pharmaceutical products provider Lannett Company (LCI) is a puzzle. Lannett shares jumped as much as 50% today, before trimming back some gains …
Did an iceberg just wallop into Conatus (CNAT) stock? This biotech company’s shares plunged yesterday at breakneck speed of almost 70%.
